Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia
NCT00969072
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
121
Enrollment
INDUSTRY
Sponsor class
Conditions
Benign Prostatic Hyperplasia
Prostatic Hyperplasia
Interventions
DRUG:
GI198745 0.05mg
DRUG:
GI198745 0.5mg
DRUG:
GI198745 2.5mg
Sponsor
GlaxoSmithKline